Reference 2017-603

REF:            2017-603

Subject:        Urothelial Cell Cancer

 

 

Request:

How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust: (diagnosed between 01/5/2017 and15/11/2017)

 Patient Type Total number of patients (treated and not treated) Number currently treated with any active anti-cancer drug treatment  (excl. surgery/ radiotherapy only) Number not treated
All Urothelial cancer (UCC, transitional carcinoma, TCC) patients      
Metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients      

 

Of the metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients, please state the number of patients currently being treated with the following therapies:

Therapy Number of metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients currently treated
Cisplatinum single agent  
Cisplatinum in combination with another agent  
Carboplatinum single agent  
Carboplatinum in combination with another agent  
Any other chemo regimen without cisplatinum or carboplatinum  
Pembrolizumab (Keytruda)  
Atezolizumab (Tecentriq)  

 

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust patients are referred:

 

 

 

 

Response:

Please find information attached.

2017-603 – FOI Request – Urothelial Cell Cancer [113 kb] PDF